Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Ezatiostat Hydrochloride

A liposomal small-molecule glutathione analog inhibitor of glutathione S-transferase (GST) P1-1 with hematopoiesis-stimulating activity. After… Expand
National Institutes of Health

Related topics

Related topics

2 relations
EzatiostatTLK-199

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Novel combinations to improve hematopoiesis in myelodysplastic syndrome
Myelodysplastic syndrome (MDS) represents a heterogeneous group of clonal hematopoietic disorders, which is characterized by… Expand
  • figure 1
2019
2019
Contributions of enzymes and gut microbes to biotransformation of perfluorooctane sulfonamide in earthworms (Eisenia fetida).
Perfluorooctane sulfonamide (FOSA) is known as a key intermediate of perfluorooctane sulfonic acid (PFOS) precursors, which can… Expand
Review
2015
Review
2015
Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes
Introduction: Myelodysplastic syndromes (MDSs) are associated with significant morbidity due to ineffective hematopoiesis. Given… Expand
2012
2012
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
BackgroundEzatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and… Expand
  • table 1
  • table 2
  • table 4
  • table 3
  • table 5
2012
2012
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
BackgroundApproximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
2011
2011
Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk…
Abstract 2778 Introduction: Lenalidomide is approved for the treatment of del(5q) MDS in US and Japan. In Low to Intermediate-1… Expand
2011
2011
Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199)
Abstract 2779 Interpretation of gene expression studies in MDS have been especially challenging due to the heterogeneity of the… Expand
2011
2011
Abstract 3246: Synthesis and biochemical characterization of novel analogues of ezatiostat hydrochloride (TLK199, Telintra®)
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Ezatiostat hydrochloride (TLK199, Telintra®) is the… Expand
Highly Cited
2009
Highly Cited
2009
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.
Phase 1 testing of ezatiostat, a glutathione S-transferase P1-1 inhibitor, for the treatment of myelodysplastic syndrome was… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2009
2009
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
BackgroundEzatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1 inhibitor, was evaluated in… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE